Medpace Holdings, Inc. (NASDAQ:MEDP – Get Free Report) CEO August Troendle sold 5,534 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $601.53, for a total transaction of $3,328,867.02. Following the completion of the sale, the chief executive officer owned 633,412 shares of the company’s stock, valued at $381,016,320.36. This trade represents a 0.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Medpace Trading Down 0.6%
Shares of MEDP opened at $578.50 on Friday. The firm’s 50-day moving average is $536.23 and its two-hundred day moving average is $492.35. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The firm has a market capitalization of $16.15 billion, a P/E ratio of 33.91, a PEG ratio of 2.60 and a beta of 1.15.
Medpace (NASDAQ:MEDP – Get Free Report) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. During the same period last year, the firm earned $3.10 EPS. The company’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current year.
Analyst Ratings Changes
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the stock. NewEdge Advisors LLC lifted its holdings in shares of Medpace by 22.1% during the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after acquiring an additional 190 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Medpace by 3.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after purchasing an additional 3,010 shares during the period. Geneos Wealth Management Inc. increased its position in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in Medpace during the second quarter worth approximately $296,000. Finally, M&T Bank Corp raised its stake in Medpace by 3.4% during the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after purchasing an additional 31 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.
About Medpace
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Featured Articles
- Five stocks we like better than Medpace
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
